BiotechTube
OraSure Technologies

OraSure Technologies

OSURPre-clinical
Bethlehem, United StatesFounded 1987500-1000 employeesorasur.com

OraSure Technologies specializes in the development, manufacture, and distribution of rapid diagnostic tests and collection devices for infectious diseases, substance abuse, and other health conditions. Its core innovation lies in oral fluid (saliva) diagnostics, which offer a less invasive alternative to blood draws. The company has achieved significant commercial success with its OraQuick® rapid HIV test and played a major role in the COVID-19 pandemic response with its InteliSwab® rapid antigen test and molecular collection kits. OraSure operates as a publicly traded entity, focusing on expanding its infectious disease portfolio and leveraging its platform for new market opportunities.

Market Cap
$212.9M
-11.7% period
Pipeline
—
Patents
—
Publications
—

OSUR · Stock Price

USD 3.080.41 (-11.75%)

Historical price data

AI Company Overview

OraSure Technologies specializes in the development, manufacture, and distribution of rapid diagnostic tests and collection devices for infectious diseases, substance abuse, and other health conditions. Its core innovation lies in oral fluid (saliva) diagnostics, which offer a less invasive alternative to blood draws. The company has achieved significant commercial success with its OraQuick® rapid HIV test and played a major role in the COVID-19 pandemic response with its InteliSwab® rapid antigen test and molecular collection kits. OraSure operates as a publicly traded entity, focusing on expanding its infectious disease portfolio and leveraging its platform for new market opportunities.

Infectious DiseaseSubstance Abuse

Technology Platform

Proprietary oral fluid (saliva) immunoassay and specimen collection platform for rapid, point-of-care, and at-home diagnostic testing, enabling non-invasive detection of infectious diseases and other conditions.

Funding History

2
Total raised:$100M
Debt$100MAug 15, 2021
IPOUndisclosedJun 15, 2000

Opportunities

Significant growth opportunity lies in the widespread adoption of its OraQuick HCV test following updated screening guidelines.
Expanding the oral fluid platform into multiplex tests for sexual health or other infectious diseases and leveraging its brand in international markets, particularly for HIV self-testing, present additional avenues for growth.

Risk Factors

Key risks include a sharp post-pandemic revenue decline, intense price competition in the COVID-19 and rapid test markets, regulatory hurdles for new product approvals, and dependence on the successful commercialization of new pipeline products to drive future growth.

Competitive Landscape

OraSure faces competition from large diagnostics companies like Abbott and QuidelOrtho in rapid tests, and lab service giants like Quest and LabCorp. Its main differentiation is its proven leadership and proprietary technology in oral fluid-based diagnostics, which offers a unique patient-friendly alternative to blood-based testing.